Standard BioTools Inc (NASDAQ: LAB) open the trading on Wednesday, with great promise as it jumped 6.62% to $1.45, before settling in for the price of $1.36 at the close. Taking a more long-term approach, LAB posted a 52-week range of $0.92-$2.41.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 11.61%. Meanwhile, its Annual Earning per share during the time was 11.61%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 55.47%. This publicly-traded company’s shares outstanding now amounts to $379.09 million, simultaneously with a float of $367.76 million. The organization now has a market capitalization sitting at $550.74 million. At the time of writing, stock’s 50-day Moving Average stood at $1.1560, while the 200-day Moving Average is $1.4465.
Standard BioTools Inc (LAB) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Medical Devices industry. Standard BioTools Inc’s current insider ownership accounts for 3.18%, in contrast to 72.15% institutional ownership. According to the most recent insider trade that took place on May 23 ’25, this organization’s Chief Financial Officer sold 1,428 shares at the rate of 0.94, making the entire transaction reach 1,344 in total value, affecting insider ownership by 930,286. Preceding that transaction, on May 23 ’25, Company’s SVP & Chief Business Officer sold 13,217 for 0.94, making the whole transaction’s value amount to 12,437. This particular insider is now the holder of 843,076 in total.
Standard BioTools Inc (LAB) Earnings and Revenue Records
Standard BioTools Inc’s EPS increase for this current 12-month fiscal period is 55.47% and is forecasted to reach -0.15 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 66.44% through the next 5 years, which can be compared against the 11.61% growth it accomplished over the previous five years trading on the market.
Standard BioTools Inc (NASDAQ: LAB) Trading Performance Indicators
Let’s observe the current performance indicators for Standard BioTools Inc (LAB). It’s Quick Ratio in the last reported quarter now stands at 5.37. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 3.25.
In the same vein, LAB’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.36, a figure that is expected to reach -0.07 in the next quarter, and analysts are predicting that it will be -0.15 at the market close of one year from today.
Technical Analysis of Standard BioTools Inc (LAB)
[Standard BioTools Inc, LAB] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 66.93% While, its Average True Range was 71.75%.
Raw Stochastic average of Standard BioTools Inc (LAB) in the period of the previous 100 days is set at 79.10%, which indicates a major fall in contrast to 83.33% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.0742 that was lower than 0.0877 volatility it exhibited in the past 100-days period.
